


Valproic acid

Cat. No.:	HY-10585												
CAS No.:	99-66-1												
Molecular Formula:	C ₈ H ₁₆ O ₂												
Molecular Weight:	144.21												
Target:	HDAC; Autophagy; Mitophagy; HIV; Notch; Apoptosis; Endogenous Metabolite												
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Autophagy; Anti-infection; Neuronal Signaling; Stem Cell/Wnt; Apoptosis; Metabolic Enzyme/Protease												
Storage:	<table border="0"> <tr> <td>Pure form</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Pure form	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Pure form	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (693.43 mM; Need ultrasonic)
 H₂O : 1 mg/mL (6.93 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	6.9343 mL	34.6717 mL	69.3433 mL
	5 mM	1.3869 mL	6.9343 mL	13.8687 mL
	10 mM	0.6934 mL	3.4672 mL	6.9343 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (693.43 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- Add each solvent one by one: 0.5% CMC/saline water
Solubility: 20 mg/mL (138.69 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (17.34 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (17.34 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (17.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μ

	M), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches ^{[1][2][3][4][5][6][7]} .																											
IC ₅₀ & Target	HDAC1 400 μM (IC ₅₀)	HDAC 0.5-2 mM (IC ₅₀)	HDAC2	Autophagy																								
	Mitophagy																											
In Vitro	<p>Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits HeLa cell growth in a dose- and time- dependent manner^[1]. Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs^[1]. Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release^[1]. Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium^[2]. Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells^[2]. Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes^[5]. Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells^[6]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 3, 5, 10 and 15 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 and 72 h</td> </tr> <tr> <td>Result:</td> <td>HeLa cell growth was dose- and time-dependently decreased with an IC₅₀ of ~10 and 4 mM at 24 and 72 h.</td> </tr> </table> <p>Western Blot Analysis^{[1][2][5]}</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells, Neuro2A cells or primary mouse hepatocytes</td> </tr> <tr> <td>Concentration:</td> <td>10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 mM (hepatocytes)</td> </tr> <tr> <td>Incubation Time:</td> <td>10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 Mm (hepatocytes)</td> </tr> <tr> <td>Result:</td> <td>Increased the form of acetylated histone 3. Reduced PARP, induced cleavage PARP, and downregulated Bcl-2. Increased β-catenin levels. Increased the phosphorylation of AMPK and ACC.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 3, 5, 10 and 15 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Induced a G1 phase arrest at 1–3 mM, significantly induced a G2/M phase arrest at 10 mM, and increased the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h.</td> </tr> </table>				Cell Line:	HeLa cells	Concentration:	0, 1, 3, 5, 10 and 15 mM	Incubation Time:	24 and 72 h	Result:	HeLa cell growth was dose- and time-dependently decreased with an IC ₅₀ of ~10 and 4 mM at 24 and 72 h.	Cell Line:	HeLa cells, Neuro2A cells or primary mouse hepatocytes	Concentration:	10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 mM (hepatocytes)	Incubation Time:	10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 Mm (hepatocytes)	Result:	Increased the form of acetylated histone 3. Reduced PARP, induced cleavage PARP, and downregulated Bcl-2. Increased β-catenin levels. Increased the phosphorylation of AMPK and ACC.	Cell Line:	HeLa cells	Concentration:	0, 1, 3, 5, 10 and 15 mM	Incubation Time:	24 h	Result:	Induced a G1 phase arrest at 1–3 mM, significantly induced a G2/M phase arrest at 10 mM, and increased the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h.
	Cell Line:	HeLa cells																										
	Concentration:	0, 1, 3, 5, 10 and 15 mM																										
	Incubation Time:	24 and 72 h																										
	Result:	HeLa cell growth was dose- and time-dependently decreased with an IC ₅₀ of ~10 and 4 mM at 24 and 72 h.																										
	Cell Line:	HeLa cells, Neuro2A cells or primary mouse hepatocytes																										
	Concentration:	10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 mM (hepatocytes)																										
	Incubation Time:	10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 Mm (hepatocytes)																										
	Result:	Increased the form of acetylated histone 3. Reduced PARP, induced cleavage PARP, and downregulated Bcl-2. Increased β-catenin levels. Increased the phosphorylation of AMPK and ACC.																										
	Cell Line:	HeLa cells																										
Concentration:	0, 1, 3, 5, 10 and 15 mM																											
Incubation Time:	24 h																											
Result:	Induced a G1 phase arrest at 1–3 mM, significantly induced a G2/M phase arrest at 10 mM, and increased the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h.																											
In Vivo	Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells ^[3]																											

Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats^[4].

Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c nude mice, Kasumi-1 tumor model ^[3]
Dosage:	500 mg/kg
Administration:	Intraperitoneal injection, daily for 12 days
Result:	Inhibited tumor growth and tumor angiogenesis. Inhibited the mRNA and protein expression of VEGF, VEGFR2 and bFGF. Inhibited HDAC activity and increased acetylation of histone H3. Enhanced the accumulation of hyperacetylated histone H3 on VEGF promoters.
Animal Model:	Timed-pregnant Long Evans rats ^[4]
Dosage:	350 mg/kg
Administration:	Intraperitoneal injection, once
Result:	Demonstrated more social investigation and play fighting than control animals.
Animal Model:	Obese phenotype of ob/ob mice ^[5]
Dosage:	0.26% (w/v)
Administration:	Oral via drinking water, 14 days
Result:	Revealed a marked reduction in the accumulation of fats in the liver as compared with the untreated mice, significantly decreased liver mass to body mass, decreased serum triglyceride concentrations, and did not induce hepatotoxicity.

CUSTOMER VALIDATION

- Sci Adv. 2021 Aug 11;7(33):eabf4416.
- Biomaterials. 2018 Dec 6;193:30-46.
- EMBO J. 2021 Apr 28;e106771.
- Oncogene. 2021 Apr;40(15):2711-2724.
- Sci Total Environ. 2021, 147014.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Routy JP, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012 May;13(5):291-6.

-
- [2]. Han BR, et al. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. *Oncol Rep.* 2013 Dec;30(6):2999-3005.
- [3]. Zhang ZH, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi 1 leukemia cells. *Mol Med Rep.* 2013 Nov 28.
- [4]. Cohen OS, et al. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. *Int J Dev Neurosci.* 2013 Dec;31(8):740-50.
- [5]. Avery LB, et al. Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. *Mol Pharmacol.* 2014 Jan;85(1):1-10.
- [6]. Valproic acid, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J Biol Chem.* 2001 Sep 28;276(39):36734-41.
- [7]. Platta CS, et al. Valproic acid induces Notch1 signaling in small cell lung cancer cells. *J Surg Res.* 2008 Jul;148(1):31-7.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA